Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Madrigal

CoreWeave and Madrigal's Insider Trades Flash Bullish Signals

Insider trades at NVIDIA-backed CoreWeave and Madrigal Pharmaceuticals are bullish indicators, but for very different reasons.

MarketBeat

Novo Nordisk Rallied On Wegovy's Newest Approval. But This Rival Rallied More.

Novo Nordisk stock jumped Monday after the FDA approved the company's obesity drug, Wegovy, as a treatment for MASH.

Investors Business Daily

Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH

Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'

Acadia Pharmaceuticals led a biotech stock sell-off Wednesday after revenue from its Rett syndrome treatment missed expectations.

Investors Business Daily

Madrigal, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH

Madrigal stock plummeted Wednesday on detailed results from a study of Eli Lilly's weight-loss drug in patients with a serious liver disease.

Investors Business Daily

US Approves First Drug For Severe Form Of Fatty Liver Disease

The US Food and Drug Administration (FDA) on Thursday approved the first medication for people with a severe type of non-alcoholic fatty liver disease.

International Business Times

Madrigal Stock Soars 11% After FDA Approved The First MASH Treatment

After a bumpy road, Madrigal gained FDA approval for the first-ever MASH treatment, Rezdiffra, and Madrigal stock skyrocketed.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Weight-Loss Tizzy: Why Altimmune Surged 23% As Others Tumbled On A New Study

Biotech stocks Madrigal and Altimmune diverged Monday as Wall Street debated the outcome of a weight-loss study in MASH patients.

Investors Business Daily

Madrigal Pharmaceuticals Surges As Its NASH Treatment Toes The Long-Awaited Finish Line

Madrigal said Wednesday it could win FDA approval for its nonalcoholic steatohepatitis treatment in March, and MDGL stock jumped.

Investors Business Daily

Madrigal Stock Pops As It Makes Inroads Into What Could Be A $160 Billion Market

Madrigal said Friday it plans to finish submitting its application for approval of a NASH treatment in July, and MDGL stock popped.

Investors Business Daily

Why Top 1% Biotech Madrigal Pharmaceuticals Just Surged Closer To A Breakout

Madrigal snagged a breakthrough therapy designation for its liver disease treatment on Tuesday and MDGL stock surged closer to a buy point.

Investors Business Daily

Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another Obstacle

Intercept Pharmaceuticals said Friday its experimental liver disease treatment will face an FDA panel in May, leading ICPT stock to tumble.

Investors Business Daily

Madrigal Pharma Stock Soars 268% After Knocking NASH Study Out Of The Park

Madrigal scored a win in the particularly tricky NASH field on Monday after its study hit both its goals, sending MDGL stock flying.

Investors Business Daily

Analysts Believe Madrigal's Resmetirom Shows Impressive Overall Profile In Liver Fibrosis

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) presented multiple resmetirom abstracts at the European Association for the Study of the Liver's International Liver Congress. The data included new details on changes in FibroScan controlled attenuation parameter and liver stiffness measurement along with magnetic resonance elastography, which serves as critical non-invasive measures of liver stiffness and fibrosis. …

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Madrigal Announces Debt Funding Of $250M To Back Potential US Resmetirom Launch

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) secured a $250 million term loan facility from Hercules Capital Inc (NYSE:HTGC), providing additional funding to support the expanded clinical program and ramp-up for a potential US launch of resmetirom. The company drew $50 million from the facility at closing and can draw a further $200 million under the agreement. Related…

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.